Novo Nordisk's September 21 investor day puts strategy and semaglutide outlook on the table

Novo Nordisk will lay out its strategy, operations and financial targets at a Capital Markets Day in London on September 21 — the first such investor meeting under chief executive Mike Doustdar ^[1]. Analysts have said they are hoping for more answers from Novo's top management at the event ^[1].

The meeting comes at an odd moment. The company's shares closed at $44.56 on September 9, closer to their 52-week low of $35.12 than to the $64.16 high reached a year earlier ^[2]. The Street's average price target sits at roughly $47, barely above the current price, and analysts are split: Deutsche Bank and Citi rate the stock Sell, while Berenberg, Argus and JPMorgan are at Hold or Neutral ^[2].

That gap exists even though the second quarter, reported August 4, beat expectations. Revenue came in at DKK 78,488 million against a Street estimate of DKK 71,535 million, a 9.72% beat, and adjusted earnings per share of 6.18 topped the 4.98 consensus by 24% ^[2]. Adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11% ^[2]. Obesity sales grew 16% in the quarter ^[2]. Novo raised full-year guidance for the second time this year, but to a still-cautious range of 0% to -6% adjusted sales growth at constant currencies ^[2].

Pipeline setbacks and the semaglutide question

On September 7, Novo halted two cardiovascular trials of its experimental drug ziltivekimab, HERMES and ATHENA, after a data monitoring committee found they were unlikely to succeed ^[2]. That followed the July failure of the ZEUS outcomes trial, in which the drug lowered inflammation markers but did not reduce major adverse cardiovascular events, with a hazard ratio of 0.99 ^[2]. Novo has been reported to be taking a non-cash impairment charge tied to the program in the third quarter, but the company has not disclosed the figure ^[2].

The same day brought a win: the STEP Young pediatric trial met its primary endpoint, with 40.4% of children aged 6 to under 12 no longer classified as obese after 68 weeks ^[2]. Shares still fell ^[2]. Chief Scientific Officer Martin Lange told analysts the cardiovascular program had carried a probability of technical success of around 50% or less ^[2]. The surviving ARTEMIS heart-attack trial is expected to read out in the first half of 2027 ^[2].

On the commercial side, chief financial officer Karsten Knudsen told analysts the second half of 2026 absorbs the loss of exclusivity for semaglutide in markets including Canada and Brazil, plus a tough comparison against roughly DKK 5 billion of one-time favorable rebate effects booked in late 2025 ^[2]. Management declined to guide on 2027 and deferred that to February ^[2]. How Novo defends semaglutide's economics as patents expire through the 2030s is one of the questions analysts want addressed at the investor day ^[1].

The oral Wegovy rollout

Novo's strongest talking point going in is the oral form of Wegovy. Jamey Millar, executive vice president of U.S. operations, called it "the strongest ever GLP-1 launch by volume," now past five million total prescriptions, with the latest million added in four weeks, and holding around 90% of the U.S. oral obesity market ^[2].

In the United Kingdom, three weeks into launch, Novo estimated around 300,000 patients had started on the pill, lifting its U.K. obesity market share from about 30% to 45% on IQVIA sell-in data, with only 1.6 million of an estimated 20 million obese U.K. adults currently treated ^[2]. Germany launched in September, with China behind it ^[2].

Why it matters for patients

The investor day matters to people taking or considering these medicines mainly through what it says about price, supply and staying power. Novo's U.S. pricing path is the main open question hanging over the stock, and the company has not yet given 2027 guidance or a timeline for when pricing stabilizes ^[2]. Until that changes, how much patients pay for semaglutide products in the U.S. remains unsettled.

Manufacturing capacity is another item analysts have flagged as needing clarity, in part because supply problems have disrupted access to obesity drugs before ^[1]. Specific capacity figures have not been disclosed ahead of the meeting ^[1].

Pipeline diversity also has a patient-facing angle. Novo's attempts to show that its medicines do more than treat diabetes and obesity have narrowed twice in two months with the ziltivekimab setbacks ^[2]. The pediatric STEP Young result shows the obesity franchise reaching a younger age group, with 40.4% of children aged 6 to under 12 no longer classified as obese after 68 weeks ^[2], but the sources do not indicate whether or when that would change approved use.

What happens next

September 21 is the date of the Capital Markets Day in London ^[1][2]. Novo has said it will give a full review of strategy, operations and financial targets there ^[1]. Management has deferred 2027 financial guidance to February ^[2]. A U.S. obesity decision for CagriSema is expected at the end of 2026, and the ARTEMIS cardiovascular trial is expected to read out in the first half of 2027 ^[2].